BA
FLGT icon

Bridgewater Associates’s Fulgent Genetics FLGT Stock Holding History

Bridgewater Associates’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,901
Closed -$410K – 899
2024
Q1 		$410K Sell
18,901
-2,911
-13% -$72.3K ﹤0.01% 639
2023
Q4 		$631K Sell
21,812
-2,751
-11% -$73.6K ﹤0.01% 684
2023
Q3 		$657K Buy
24,563
+2,402
+11% +$82K ﹤0.01% 665
2023
Q2 		$821K Sell
22,161
-1,223
-5% -$42.6K 0.01% 605
2023
Q1 		$730K Buy
23,384
+792
+4% +$25.5K ﹤0.01% 598
2022
Q4 		$673K Sell
22,592
-10,726
-32% -$384K ﹤0.01% 691
2022
Q3 		$1.27M Buy
33,318
+1,374
+4% +$68.9K 0.01% 653
2022
Q2 		$1.74M Buy
31,944
+3,006
+10% +$165K 0.01% 708
2022
Q1 		$1.81M Buy
28,938
+6,929
+31% +$456K 0.01% 704
2021
Q4 		$2.21M Sell
22,009
-5,761
-21% -$506K 0.01% 450
2021
Q3 		$2.5M Sell
27,770
-2,083
-7% -$189K 0.01% 404
2021
Q2 		$2.75M Buy
+29,853
New +$2.38M 0.02% 435

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bridgewater Associates's FLGT Position: Q2 2024 in Review

Bridgewater Associates sold out of Fulgent Genetics (FLGT) in Q2 2024, closing a stake of 18,901 shares — an estimated $410K sold.

Bridgewater Associates first reported a position in FLGT in Q2 2021 and held it in 12 quarters. The position peaked at $2.75M in Q2 2021. 173 funds tracked by Wall St. Rank hold FLGT as of Q2 2024.

  • Bridgewater Associates reported no remaining Fulgent Genetics position as of Q2 2024 after selling out during the quarter.
  • Bridgewater Associates sold 18,901 Fulgent Genetics shares in Q2 2024, an estimated $410K.
  • Bridgewater Associates first reported a position in Fulgent Genetics in Q2 2021 and held it in 12 quarters.
  • Bridgewater Associates's Fulgent Genetics position peaked at $2.75M in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2024.

Based on Bridgewater Associates's 13F filing for Q2 2024, filed 14 Aug 2024.